Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant human alpha synuclein produced in E. coli.|
|Purification||Ammonium sulfate precipitation|
|Contains||0.1% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Dot blot (DB)||1:100-1:10,000|
|ELISA (ELISA)||Assay dependent|
|Immunohistochemistry (Frozen) (IHC (F))||1:100-1:1000|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100-1:1000|
|Western Blot (WB)||1:100-1:10,000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunocytochemistry (ICC)||See 1 publications below|
MA1-90346 detects alpha Synuclein from human samples. Does not cross react with mouse and rat samples.
MA1-90346 has been successfully used in ELISA, immunohistochemistry (frozen tissue), immunohistochemistry (paraffin tissue), Dot blot and Western blot applications. Predicted molecular weight of 16 kDa.
The MA1-90346 immunogen is recombinant human alpha synuclein produced in E. coli.
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
A prolyl oligopeptidase inhibitor, KYP-2047, reduces ¿-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
MA1-90346 was used in immunocytochemistry, immunohistochemistry, and western blot to study the reduction in the levels of alpha-synuclein protein and aggregation by a prolyl peptidase inhibitor in various models of Parkinson's disease
|Myöhänen TT,Hannula MJ,Van Elzen R,Gerard M,Van Der Veken P,García-Horsman JA,Baekelandt V,Männistö PT,Lambeir AM||British journal of pharmacology (166:1097)||2012|
Alpha-synuclein; NACP; non A-beta component of AD amyloid; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; synuclein alpha-140; synuclein, alpha (non A4 component of amyloid precursor)
NACP; PARK1; PARK4; PD1; SNCA